Shares of CXMT surged 4.7% to CNY 57.38 after fresh data confirmed what Korean chipmakers feared: China's ChangXin Memory Technologies captured a double-digit share of the global DRAM market for the first time, accounting for 10% of global DRAM revenue in Q2 2026. For investors, the question is whether a company riding a once-in-a-decade pricing boom can hold its ground when the cycle turns.
• A Market Opening That Rivals Accidentally Created
Total DRAM revenue surged 385% year-over-year in Q2 as Samsung, SK Hynix, and Micron redirected advanced manufacturing toward AI memory chips, with Micron noting each wafer shifted to AI removed three standard-memory wafers from the market. CXMT stepped into that vacancy.
CXMT's revenue surged 716% year-over-year , but shareholders should understand the gains came partly from an extraordinary supply squeeze, not just execution.
• The Big Three's Grip Has Loosened for the First Time in a Decade
Samsung led with 38%, SK Hynix at 25%, and Micron at 24% — meaning the legacy Big Three now command 87% of global DRAM revenue, a figure that for any quarter in the past decade would have read closer to 94% or above.
Both Counterpoint Research and UBS had projected CXMT would not reach 10% in shipment share until 2028 — the company is two years ahead of schedule. That timeline compression is what moved the stock.
• Expansion Plans Are Massive — and Risky
CXMT's current monthly wafer capacity is around 300,000, and it expects to expand to 550,000–600,000 by 2028, approaching SK Hynix's roughly 590,000.
With 183 billion yuan ($25.3 billion) in fixed assets and annual depreciation topping 10 billion yuan, a drop in memory prices would hit CXMT's bottom line hard.
Goldman Sachs expects supply shortages to run through 2027, while Bloomberg Intelligence warns oversupply could return as early as 2028 if cloud spending cools.
• A Cost Gap Still Stands Between CXMT and Its Rivals
CXMT completed its transition to a roughly 16nm-class process with yields above 90%, but due to reliance on multi-patterning — extra manufacturing steps needed to work around U.S. equipment bans — the company remains at a disadvantage in cost-per-chip versus leading competitors. In a downturn, that cost gap could erase the market-share gains investors are celebrating today.